Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Japanese Adult Subjects With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
NCT06649006Phase 1Completed
- Sponsor
- Amgen
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Primary endpoints: Treatment-emergent Adverse Events and Adverse Events of Interest. Started Jan 2025; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06649006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649006.